---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-092495"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2024-08-23T23:59:59+00:00"
generated_at: "2026-05-31T07:48:17.462325+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cellectar to restate financial statements, receives Nasdaq delinquency notice for late Q2 filing

## Summary
- Restating audited FY2022 & FY2023 and unaudited Q1-Q3 2023 & Q1 2024 due to warrant accounting error in Oct 2022 financing.
- Changes are non-cash and non-operating; restatement expected to take ~6 weeks before filing Q2 2024 10-Q.
- Received Nasdaq notice on Aug 20, 2024 for late Q2 10-Q; must submit compliance plan by Oct 21, 2024.
- Nasdaq may grant up to 180-day extension (until Feb 17, 2025) if plan accepted; otherwise can appeal.
- No immediate delisting impact, but failure to regain compliance could lead to listing suspension.

## SEC filing metadata
- accession: 0001104659-24-092495
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2024-08-23T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465924092495/0001104659-24-092495-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465924092495/tm2422595d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-092495
- JSON: https://secwatch.observer/filing/0001104659-24-092495.json
- Plain text: https://secwatch.observer/filing/0001104659-24-092495.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.